Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease

Tejaswini Kulkarni, Audrey Haywood, Anoop M Nambiar

1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham AL, USA; 2. Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center at San Antonio, TX, USA; 3. South Texas Veterans Health Care System, San Antonio, TX, USA

Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis of the skin and other internal organs, especially the lungs. SSc-associated interstitial lung disease (SSc-ILD) is the most common complication of SSc and leading cause of morbidity and mortality in these patients. As such, there is a significant unmet need for earlier, more accurate diagnosis and implementation of safer, more effective therapies. The pathogenesis of SSc-ILD is a complex process that involves cellular and humoral immune dysregulation, inflammatory mediators, and vascular and fibrotic mechanisms. Traditional therapeutic strategies have focused on reducing chronic inflammation and the immunomodulation. Mycophenolate mofetil is currently considered the first-line therapy for SSc-ILD based on the Scleroderma Lung Study (SLS-II) trial which showed equivalent efficacy with fewer adverse events compared to cyclophosphamide. Nintedanib is an intracellular tyrosine kinase inhibitor with antifibrotic, anti-inflammatory, and vascular remodeling effects. Currently approved for idiopathic pulmonary fibrosis, nintedanib was recently evaluated for safety and efficacy in SSc-ILD. Based upon the results of this pivotal trial, nintedanib is the first ever treatment approved by the US Food and Drug Administration for SSc-ILD. This review focuses on the pathogenesis of SSc-ILD and the role of nintedanib in the treatment algorithm for these patients.

Keywords
Systemic sclerosis, scleroderma, interstitial lung disease, nintedanib

Disclosure: Tejaswini Kulkarni, Audrey Haywood and Anoop M Nambiar have nothing to disclose in relation to this article.


Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authors: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Access: This article is freely accessible at touchRESPIRATORY.com. © Touch Medical Media 2020.

Received: January 7, 2020
Accepted: February 25, 2020
Published Online: April 9, 2020
Citation: US Respiratory and Pulmonary Diseases. 2020;5(1):Epub ahead of print.

Corresponding Author: Anoop M Nambiar, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7885, San Antonio, TX, USA 78229. E: nambiar@uthscsa.edu

Support: No funding was received for the publication of this article.
interstitial lung disease (ILD) is the most common pulmonary manifestation of SSc. The reported prevalence of ILD in patients with SSc may be up to 90%, but varies depending on the distribution of serological pattern, definition of ILD, and the population studied (e.g., lcSSc, dcSSc, or a combination). While restrictive lung disease does occur in both lcSSc and dcSSc, it appears to occur with higher frequency in dcSSc. The incidence of ILD is highest among the subgroup of patients with anti-topoisomerase I antibody (anti-Scl-70) positivity and dcSSc. Presence of anti-Scl-70 antibodies has been associated with lower and more rapid decline in forced vital capacity (FVC), while presence of anti-centromere antibodies has been associated with less restriction, isolated diffusion defects, and pulmonary hypertension. Radiographic findings of ILD have also been shown to be less frequent in the presence of anti-centromere antibodies. Additional patient characteristics such as gender and race may potentially contribute to the development of ILD among patients with SSc.

Clinical considerations
ILD is the most common pulmonary manifestation of SSc. The reported prevalence of ILD in patients with SSc may be up to 90%, but varies depending on the distribution of serological pattern, definition of ILD, and the population studied (e.g., lcSSc, dcSSc, or a combination). While restrictive lung disease does occur in both lcSSc and dcSSc, it appears to occur with higher frequency in dcSSc. The incidence of ILD is highest among the subgroup of patients with anti-topoisomerase I antibody (anti-Scl-70) positivity and dcSSc. Presence of anti-Scl-70 antibodies has been associated with lower and more rapid decline in forced vital capacity (FVC), while presence of anti-centromere antibodies has been associated with less restriction, isolated diffusion defects, and pulmonary hypertension. Radiographic findings of ILD have also been shown to be less frequent in the presence of anti-centromere antibodies. Additional patient characteristics such as gender and race may potentially contribute to the development of ILD among patients with SSc.

Presenting symptoms generally include dyspnea, fatigue, reduced exercise capacity, and cough. Exam findings, including fine, bibasilar, and inspiratory crackles, may suggest underlying ILD, and should prompt further evaluation with pulmonary function tests (PFTs), high-resolution computed tomography (HRCT) chest scans, and/or echocardiogram. PFT abnormalities including restriction and diffusion capacity deficits have been demonstrated in >70% of patients, although several patients may have normal lung function in the presence of early ILD. Radiographic findings consistent with fibrosis were seen in at least one-third of patients with scleroderma, while some other studies have reported prevalence up to 90%. Nevertheless, given the progressive nature of pulmonary fibrosis, early evaluation with HRCT is warranted, particularly among patients with risk factors. The most common pattern of fibrosis on HRCT in SSC-ILD is nonspecific interstitial pneumonia (NSIP) with ground-glass opacities and subpleural sparing. Usual interstitial pneumonia pattern, characterized by basal predominant peripheral reticulations, traction bronchiectasis, and honeycomb changes, is present in one-third of these patients and portends a poorer prognosis. The NSIP histology tends to be the fibrotic form more often than cellular NSIP, but the prognosis has not been shown to differ between the types of NSIP. Among patients with a histopathologic pattern of usual interstitial pneumonia, SSc is associated with increased presence of lymphocytic infiltrates compared to those with IPF.

Current therapies
Therapies for ILD related to SSc have traditionally focused on reducing the chronic inflammation that is believed to lead to fibrosis. These often include corticosteroids and other immunosuppressive agents. Despite these therapies, 3-year survival in patients with serious cardiac or pulmonary involvement is only about 50%. Physiologic parameters, including FVC, appear to be the best method of monitoring progression of fibrotic ILD, and most studies use FVC as the primary endpoint in evaluation of potential therapies for SSC-ILD. Key positive randomized control trials in SSc-ILD are outlined in Table 1.

Mycophenolate mofetil (MMF) is currently considered the first-line therapy for SSC-ILD based on the Scleroderma Lung Study (SLS)-II. This study was a multicenter, randomized, double-blind, parallel-group trial in 126 patients with SSc-ILD that compared the efficacy and safety of MMF (target dose of 1,500 mg twice daily) for 24 months versus oral cyclophosphamide (target dose 2 mg/kg per day) for 12 months followed by placebo for 12 months. Although there was no significant difference in the primary endpoint of change in FVC (percent predicted) at 2 years between groups, both groups were less involved in the vascular and fibrotic changes that occur in SSc. The incidence of ILD is highest among the subgroup of patients with anti-topoisomerase I antibody (anti-Scl-70) positivity and dcSSc. Presence of anti-Scl-70 antibodies has been associated with lower and more rapid decline in forced vital capacity (FVC), while presence of anti-centromere antibodies has been associated with less restriction, isolated diffusion defects, and pulmonary hypertension. Radiographic findings of ILD have also been shown to be less frequent in the presence of anti-centromere antibodies. Additional patient characteristics such as gender and race may potentially contribute to the development of ILD among patients with SSc.

There are very limited data to support the efficacy of corticosteroids in SSC-ILD, but rather evidence of risk of scleroderma renal crisis, particularly with higher doses. While a majority of patients receive corticosteroids at some point in their disease course, only a few small studies have shown marginal benefit of corticosteroid use over no immunosuppression. In a subgroup of patients with significant inflammation and ground-glass opacities on HRCT at presentation, corticosteroids might be utilized in conjunction with MMF titration. The generally accepted clinical approach focuses on cautious utilization of corticosteroids during acute exacerbations but is not recommended as a monotherapy in patients with SSC-ILD.

Azathioprine has been considered in combination therapy with cyclophosphamide, but the evidence to use it as monotherapy is less compelling. Finally, rituximab, a monoclonal antibody that targets CD20-positive B-lymphocytes, has been employed among patients with refractory or progressive ILD but the paucity of randomized controlled trials evaluating the efficacy of rituximab in SSc-ILD limits its utility. While these traditional immunosuppressive therapies have focused primarily on chronic inflammation in SSC-ILD, the advent of antifibrotic therapies approved for IPF have helped usher in a paradigm shift in the management of SSC-ILD.
Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease

### Table 1: Key randomized controlled trials for systemic sclerosis-associated interstitial lung disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Intervention</th>
<th>N</th>
<th>Primary outcome</th>
<th>Other key findings</th>
</tr>
</thead>
</table>
| Scleroderma Lung Study-II                  | Year 1: Randomized, double blind, placebo-controlled trial Year 2: Follow-up without drug | CYC ≤2 mg/kg/day; placebo   | 158 | Mean absolute difference in adjusted 12-month % FVC: 2.53% (95% CI 0.28–4.79); favoring CYC (p=0.03) | • Difference in % FVC maintained at 24 months  
• Treatment-related benefit in quality of life outcomes, skin thickening  
• More adverse events in CYC group |
| Scleroderma Lung Study-III                 | 2-year randomized, double-blind, two-arm active medication/placebo-controlled trial | Arm 1: MMF 1,500 mg twice a day (24 months) Arm 2: Cytoxan ≤2 mg/kg/day (12 months) then placebo (12 months) | 126 | % FVC improved by 2.19% (95% CI 0.53–3.84) in the MMF arm and 2.88% (95% CI 1.19–4.58) in the CYC arm (p=0.24) | • Leucopenia and thrombocytopenia were more frequent with CYC than MMF  
• Greater number of patients prematurely withdrew or failed treatment in CYC arm than MMF  
• Within treatment improvements in % FVC, skin score and whole-lung HRCT scores at 24 months in both arms in post-hoc analysis |
| Safety and Efficacy of Nintedanib in Systemic Sclerosis⁴ | 52-week randomized, double-blind, placebo-controlled trial | Nintedanib 150 mg twice a day | 576 | Adjusted annual rate of change in FVC: -52.4 mL per year in Nintedanib group and -93.3 mL per year in the placebo group (difference 41 mL/year; 95% CI 2.9–79; p=0.04) | • No difference in modified Rodnan skin score at week 52  
• Diarrhea reported in 75.7% in nintedanib group versus 31.6% in placebo group |

CI = confidence interval; CYC = cyclophosphamide; FVC = forced vital capacity; MMF = mycophenolate mofetil.

### Nintedanib and its mechanism of action

Nintedanib, an intracellular tyrosine kinase inhibitor, was shown to reduce the rate of FVC decline in patients with IPF in the INPULSIS trials (ClinicalTrials.gov identifier: NCT01619085)³⁴ and was approved for treatment of IPF at a dose of 150 mg twice daily. Several in vitro studies show that nintedanib has antifibrotic, anti-inflammatory, and vascular remodeling effects with resultant attenuation of progression of fibrosis in preclinical models of IPF.³⁵ Given the considerable similarities in the pathogenesis of IPF and SSc-ILD, particularly myofibroblast differentiation and dysregulated ECM deposition, it has been hypothesized that a similar effect of nintedanib may be seen in SSc-ILD and has been reported in in vitro studies of SSc-ILD and SSc skin fibrosis. Nintedanib was shown to inhibit the differentiation and migration of lung fibroblasts derived from patients with SSc-ILD; it also blocked PDGF-induced differentiation of normal lung fibroblasts to myofibroblasts, with resultant reduction in ECM expression.³⁶ Nintedanib has also been shown to have similar effects on dermal fibroblasts obtained from patients with SSc compared to healthy subjects.³⁷ In this study, nintedanib also prevented bleomycin-induced skin fibrosis and ameliorated fibrosis in a chronic graft-versus-host disease model and in tight-skin-1 mice. Reduction in pulmonary and dermal fibrosis demonstrated by decreased myofibroblast counts and ECM deposition has also been reported in nintedanib treated fibrosis for-related antigen 2 (Fra2)-transgenic mice.³⁸ Additionally, a significant effect on pulmonary vascular remodeling via inhibition of the proliferation of pulmonary vascular smooth muscle cells in these Fra2-transgenic mice, was demonstrated with nintedanib.³⁹

### Nintedanib—evidence from clinical trials

Based on the rationale that nintedanib can modulate the fundamental process of myofibroblast differentiation and ECM deposition in all ILDs, The Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (ClinicalTrials.gov identifier: NCT02597933) recently evaluated use of nintedanib in patients with SSC-ILD. This was a multinational, randomized, double-blind, placebo-controlled, parallel-group trial that included 576 adult patients diagnosed with SSc with HRCT chest scan showing fibrosis affecting at least 10% of the lungs, FVC of at least 40% predicted value, and the diffusing capacity of the lungs for carbon monoxide (DLCO) of 30–89% predicted value. Four of the 819 patients screened had clinically significant pulmonary hypertension defined by either clinical or echocardiographic evidence of right heart failure, cardiac index ≤2 L/minute per square of body surface area, or history of parenteral therapy with vasodilators, and were excluded from the study. Patients were randomized to either nintedanib 150 mg twice daily or placebo with primary efficacy evaluation conducted at week 52. The primary endpoint was the annual rate of decline in FVC. The trial investigators found the annual rate of change in FVC over 52 weeks to be lower in the nintedanib group (-52.4 ± 13.8 mL) compared with the placebo group (-93.3 ± 13.5 mL) with benefit becoming evident by week 12. Importantly, the benefit of nintedanib over placebo was present but less pronounced in patients taking mycophenolate at baseline compared with those not on mycophenolate. There was no improvement in health-related quality of life nor evidence that nintedanib modifies the course of other organs affected by SSc. Sixteen percent of patients in the nintedanib group experienced an adverse event that led to discontinuation compared with 8.7% of patients in the placebo group. Diarrhea was the most common adverse event, occurring in almost 76% of patients taking the drug, and was mild to moderate in most patients. About 5% of patients receiving nintedanib had elevations in aminotransferases reaching three times the upper limit of normal.¹ On September 6, 2019, nintedanib was approved by the US Food and Drug Administration (FDA) as the first and only treatment for SSC-ILD.³⁰

In addition, nintedanib was evaluated in patients with progressive fibrosing ILD, including SSC-ILD, in the INBUILD trial.³⁰ This was a randomized, double-blind, placebo-controlled trial that included a total of 663 patients,
of which 39 (5.9%) had SSC-ILD. Key inclusion criteria were fibrosing lung disease with >10% of lung volume affected based on HRCT, confirmed disease progression despite use of conventional therapies within 24 months prior to enrollment, FVC of at least 45% predicted, and DLCO of 30–79% predicted. Patients were randomized to receive either nintedanib 150 mg twice daily or placebo. The primary endpoint was annual rate of FVC decline followed over 52 weeks. The results demonstrated a statistically significant reduction in the FVC rate of decline: -80.8 mL per year in the nintedanib group and -187.8 mL per year with placebo. The difference was more pronounced in patients with a usual interstitial pneumonia-like pattern of fibrosis. Diarrhea was the most common adverse event in the nintedanib group, and more people required dose reductions or discontinuation of nintedanib when compared with placebo.40

**Treatment decision-making**

The decision to initiate treatment in patients with SSC-ILD can be a challenging one that requires integration of several patient-related and disease-specific features. Although patients with SSC-ILD may have increased mortality rates, the currently available treatments have potentially significant toxicity with only modest efficacy. Survival prediction tools, such as those by Goh et al.,41 and the SADL model by Morisset et al.,42 may be helpful in predicting short-term mortality and aid in treatment decisions. With the advent of antifibrotic therapy, a nuanced understanding of the risks and benefits of all therapeutic options in a disease previously treated with only immunosuppression is crucial. There is increasing evidence emphasizing the importance of early treatment for ILD; larger centers are now focusing on annual screening of patients with SSC with PFTs and/or HRCTs. However, guidelines for recommendation of treatment algorithms are yet to be published.

Given the potential benefit from initial immunosuppressive therapy during the inflammatory phase in SSC-ILD, MMF remains the first line of therapy given its efficacy in modulating both pulmonary and extra-pulmonary manifestations of SSC.43,44 MMF therapy has been shown to improve lung function as measured by FVC while nintedanib only slowed down disease progression in the SENSCIS trial. Further, there was only a modest additional benefit of nintedanib to MMF therapy among patients with stable disease: the annual rate of change in FVC among patients on background MMF was -40.2 mL per year in the nintedanib arm compared to -66.5 mL per year in the placebo arm.4 In the absence of randomized controlled trials evaluating MMF or cyclophosphamide versus nintedanib, we believe that nintedanib should only be utilized among patients with SSC-ILD who decline, or are intolerant to, MMF and/or cyclophosphamide therapy or demonstrate disease progression despite these initial therapies. The benefit of treatment with nintedanib over placebo (± background MMF) was noticeable only beyond the 12-week mark and should be a consideration in the treatment algorithm. As mentioned earlier, patients with clinically significant pulmonary hypertension were excluded from the SENSCIS trial; therefore, the potential benefits of nintedanib in these patients is unknown. The majority of these patients require long-term maintenance therapy to preserve their lung function and should be monitored with PFTs every 3–6 months. Overall, nintedanib was tolerated at least as well as in IPF despite known gastrointestinal issues that are common among patients with SSC. The extension trial, SENSCIS-ON, will assess the long-term safety of nintedanib in SSC-ILD and may shed more light on its utility in clinical practice.

**Conclusions**

SSC-ILD is a chronic, progressive fibrotic lung disease associated with increased mortality. Clinical practice guidelines to best inform a therapeutic approach for these patients is absent; MMF is currently considered the standard of care based on the SLS-II. However, recent studies evaluating nintedanib in SSC-ILD have been encouraging and led to FDA approval of nintedanib as the first and only for SSC-ILD. Many key questions, such as when to initiate antifibrotic therapy, how best to measure the treatment response, and how long treatment should be continued, remain unanswered. }